We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$5.06B
AUM Growth
+$476M
Cap. Flow
+$367M
Cap. Flow %
7.25%
Top 10 Hldgs %
27.38%
Holding
165
New
14
Increased
67
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
AGL icon
Agilon Health
AGL
+$245M
2
LENZ
LENZ Therapeutics
LENZ
+$53.5M
3
NEUE
NeueHealth
NEUE
+$40.7M
4
VERV
Verve Therapeutics
VERV
+$40M
5
LFST icon
Lifestance Health
LFST
+$39.6M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$100M
2
AZN icon
AstraZeneca
AZN
+$32.3M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.2M
4
INSP icon
Inspire Medical Systems
INSP
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Consumer Staples 1.63%
3 Industrials 0.71%
4 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
101
MacroGenics
MGNX
$257M
$12.2M 0.24%
455,816
+62,337
+16% +$1.83M
RYTM icon
102
Rhythm Pharmaceuticals
RYTM
$7.96B
$11.9M 0.23%
606,280
+7,000
+1% +$145K
LKFT
103
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$11.4M 0.22%
165,000
– –
PRTK
104
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.3M 0.22%
1,654,714
-30,000
-2% -$243K
SYRE icon
105
Spyre Therapeutics
SYRE
$9.25B
$11M 0.22%
63,092
– –
PRLD icon
106
Prelude Therapeutics
PRLD
$390M
$10.9M 0.22%
382,359
+4,164
+1% +$148K
XENE icon
107
Xenon Pharmaceuticals
XENE
$6.12B
$10.7M 0.21%
572,500
– –
OKUR
108
OnKure Therapeutics
OKUR
$168M
$10.5M 0.21%
+112,902
New +$12.6M
CGEN icon
109
Compugen
CGEN
$228M
$10.2M 0.2%
1,236,988
+17,500
+1% +$142K
WST icon
110
West Pharmaceutical
WST
$24.9B
$10.2M 0.2%
28,500
– –
AUPH icon
111
Aurinia Pharmaceuticals
AUPH
$2.11B
$10.2M 0.2%
785,769
+4,200
+0.5% +$53.5K
TBPH icon
112
Theravance Biopharma
TBPH
$877M
$9.98M 0.2%
687,500
+4,900
+0.7% +$92K
APLS
113
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$9.98M 0.2%
+157,900
New +$8.15M
OHPAU
114
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$9.92M 0.2%
1,000,000
– –
FOLD
115
DELISTED
Amicus Therapeutics
FOLD
$9.76M 0.19%
1,012,506
– –
KDNY
116
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$9.64M 0.19%
682,449
+9,400
+1% +$150K
STTK icon
117
Shattuck Labs
STTK
$694M
$9.09M 0.18%
313,499
-75,000
-19% -$2.19M
FSTX
118
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$9.06M 0.18%
+1,054,232
New +$8.99M
DAWN
119
DELISTED
Day One Biopharmaceuticals
DAWN
$8.51M 0.17%
+373,739
New +$7.8M
NRIX icon
120
Nurix Therapeutics
NRIX
$2.65B
$8.37M 0.17%
315,350
+4,400
+1% +$129K
CNST
121
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$8.36M 0.17%
247,200
+15,200
+7% +$387K
KYNB
122
Kyntra Bio
KYNB
$29.4M
$8.33M 0.16%
12,507
– –
KNTE
123
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$7.72M 0.15%
331,586
+5,200
+2% +$132K
LONA
124
LeonaBio Inc
LONA
$72.1M
$7.66M 0.15%
74,820
-4,000
-5% -$698K
FUSN
125
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$7.66M 0.15%
948,327
– –
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rock Springs Capital Management held 165 positions worth $5.06B, up 10% from $4.58B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $367M of net new capital in Q2 2021, opening 14 new positions and adding to 67 existing holdings. Its largest new stake was Agilon Health: 279,961 shares worth $284M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $27.2M trimmed.

  • Rock Springs Capital Management's largest Q2 2021 buy was Agilon Health: 279,961 shares worth $284M.
  • Rock Springs Capital Management added most to Eargo, Inc. Common Stock in Q2 2021, an estimated $25.1M increase.
  • Rock Springs Capital Management's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $27.2M.
  • Rock Springs Capital Management fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $100M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $5.06B portfolio in Q2 2021.
  • Rock Springs Capital Management opened 14 new positions and closed 9 in Q2 2021.
  • Rock Springs Capital Management's portfolio value rose 10% quarter-over-quarter to $5.06B.

Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.